Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193347 | 0.93 | CA2 (0.49) | NR1I2SERPINE1ALDH1A1CA2CA1 | |
| SCHEMBL3193462 | 0.92 | SERPINE1 (0.53) | NR1I2SERPINE1ALDH1A1CA2CA1 | |
| SCHEMBL3185435 | 0.88 | SERPINE1 (0.52) | NR1I2SERPINE1ALDH1A1CA2CA1 | |
| SCHEMBL3328211 | 0.88 | NTSR1 (0.59) | NR1I2SERPINE1ALDH1A1MAPTNTSR1 | |
| SCHEMBL3193084 | 0.88 | NTSR1 (0.59) | NR1I2SERPINE1ALDH1A1MAPTNTSR1 | |
| SCHEMBL3185508 | 0.85 | EPHX2 (0.62) | NR1I2SERPINE1ALDH1A1MAPTEPHX2 | |
| SCHEMBL3195444 | 0.84 | NR1I2 (0.63) | NR1I2SERPINE1ALDH1A1EPHX2NR1H4 | |
| SCHEMBL3186142 | 0.83 | FPR2 (0.53) | EPHX2NR1H4 | |
| SCHEMBL27718316 | 0.83 | FPR2 (0.53) | EPHX2NR1H4 | |
| SCHEMBL5422761 | 0.81 | EPHX2 (0.60) | NR1I2SERPINE1ALDH1A1MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | WYETH LLC (US) | 2010-06-03 | — | — | US | claimed |
| US-7683091-B2 | Substituted indoles and methods of their use | WYETH (US) | 2010-03-23 | — | — | US | claimed |
| EP-1919866-A2 | SUBSTITUTED INDOLES AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | claimed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| WO-2007022321-A2 | SUBSTITUTED INDOLES AND USE THEREOF | WYETH (US) | 2007-02-22 | — | — | WO | claimed |
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | WYETH LLC (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683091-B2 | Substituted indoles and methods of their use | WYETH (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043101-A1 | Substituted indoles and methods of their use | INMT, AANAT, IDO2 | NR1I2 2818/4885SERPINE1 4756/4885ALDH1A1 337/4885 |
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | INMT, AANAT, IDO2 | NR1I2 2818/4885SERPINE1 4756/4885ALDH1A1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.